Celcuity (NASDAQ:CELC) Announces Earnings Results, Misses Expectations By $0.13 EPS

Celcuity (NASDAQ:CELC - Get Free Report) announced its quarterly earnings data on Monday. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.72) by ($0.13), Zacks reports.

Celcuity Price Performance

Shares of Celcuity stock traded down $0.20 on Friday, hitting $8.65. The company's stock had a trading volume of 502,142 shares, compared to its average volume of 294,085. Celcuity has a 52-week low of $7.70 and a 52-week high of $20.15. The company has a market capitalization of $321.17 million, a P/E ratio of -3.31 and a beta of 0.44. The firm has a fifty day moving average price of $10.99 and a 200-day moving average price of $12.77. The company has a quick ratio of 10.36, a current ratio of 10.35 and a debt-to-equity ratio of 0.65.

Analyst Ratings Changes

A number of research analysts have recently weighed in on CELC shares. Needham & Company LLC reissued a "buy" rating and issued a $29.00 price objective on shares of Celcuity in a report on Tuesday. HC Wainwright reissued a "buy" rating and set a $27.00 price objective on shares of Celcuity in a research note on Tuesday. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus price target of $30.17.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.